1
|
Mekjaruskul C, O'Reilly Beringhs A, Qin B, Wang Y, Lu X. Impact of active pharmaceutical ingredient variables and oleaginous base on the in vitro drug release from ophthalmic ointments: An investigation using dexamethasone as a model drug. Int J Pharm 2024; 658:124184. [PMID: 38692497 DOI: 10.1016/j.ijpharm.2024.124184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 04/23/2024] [Accepted: 04/28/2024] [Indexed: 05/03/2024]
Abstract
The present study systematically investigates the impact of active pharmaceutical ingredient (API) variables and oleaginous base characteristics on the in vitro release (IVR) performance of ophthalmic ointments, utilizing dexamethasone as a model drug. The interplay between selected attributes (i.e., particle size distribution, crystallinity, and polymorphic form for API, and rheological factors for compendial-grade white petrolatum) and IVR performance was investigated. APIs from different vendors exhibited variations in crystallinity and polymorphism. Ointments containing amorphous dexamethasone presented higher release amounts/rates compared to crystalline counterparts, emphasizing the role of physical state in release kinetics. Variations in particle size of this lipophilic API (5.4 - 21.2 µm) did not appear to impact IVR performance significantly. In contrast, white petrolatum's rheological attributes, which varied substantially within USP-grade petrolatum, were found to critically affect the drug release rate and extent of the ointment. The study's comprehensive analysis establishes a coherent connection between the quality attributes of both API and petrolatum and IVR, delineating their intricate interdependent effects on ophthalmic ointment performance. These findings provide reference to formulation design, quality control, and regulatory considerations within the pharmaceutical industry, fostering a robust foundational understanding of commonly overlooked quality attributes in ophthalmic ointments.
Collapse
Affiliation(s)
- Catheleeya Mekjaruskul
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
| | - André O'Reilly Beringhs
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Bin Qin
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Yan Wang
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Xiuling Lu
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
| |
Collapse
|
2
|
Passos JS, Apolinario AC, Ishida K, Martins TS, Lopes LB. Nanostructured lipid carriers loaded into in situ gels for breast cancer local treatment. Eur J Pharm Sci 2024; 192:106638. [PMID: 37967657 DOI: 10.1016/j.ejps.2023.106638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 10/18/2023] [Accepted: 11/11/2023] [Indexed: 11/17/2023]
Abstract
In this study, nanostructured lipid carriers (NLC) were developed and employed to obtain in situ thermosensitive formulations for the ductal administration and prolonged retention of drugs as a new strategy for breast cancer local treatment. NLC size was influenced by the type and concentration of the oil phase, surfactants, and drug incorporation, ranging from 221.6 to 467.5 nm. The type of liquid lipid influenced paclitaxel and 5-fluorouracil cytotoxicity, with tributyrin-containing NLC reducing IC50 values by 2.0-7.0-fold compared to tricaprylin NLC in MCF-7, T-47D and MDA-MB-231 cells. In spheroids, the NLCs reduced IC50 compared to either drug solution (3.2-6.2-fold). Although a significant reduction (1.26 points, p < 0.001) on the health index of Galleria mellonella larvae was observed 5 days after NLC administration, survival was not significantly reduced. To produce thermosensitive gels, the NLCs were incorporated in a poloxamer (11 %, w/w) dispersion, which gained viscosity (2-fold) at 37 °C. After 24 h, ∼53 % of paclitaxel and 83 % of 5-fluorouracil were released from the NLC; incorporation in the poloxamer gel further prolonged release. Intraductal administration of NLC-loaded gel increased the permanence of hydrophilic (2.2-3.0-fold) and lipophilic (2.1-2.3-fold) fluorescent markers in the mammary tissue compared to the NLC (as dispersion) and the markers solutions. In conclusion, these results contribute to improving our understanding of nanocarrier design with increased cytotoxicity and prolonged retention for the intraductal route. Tributyrin incorporation increased the cytotoxicity of paclitaxel and 5-fluorouracil in monolayer and spheroids, while NLC incorporation in thermosensitive gels prolonged tissue retention of both hydrophilic and hydrophobic compounds.
Collapse
Affiliation(s)
- Julia S Passos
- Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, 1524 Av. Prof. Lineu Prestes, Sao Paulo SP 05508-000, Brazil
| | - Alexsandra C Apolinario
- Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, 1524 Av. Prof. Lineu Prestes, Sao Paulo SP 05508-000, Brazil
| | - Kelly Ishida
- Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil
| | - Tereza S Martins
- Department of Chemistry, Federal University of Sao Paulo (UNIFESP), Diadema, São Paulo, Brazil
| | - Luciana B Lopes
- Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, 1524 Av. Prof. Lineu Prestes, Sao Paulo SP 05508-000, Brazil.
| |
Collapse
|
3
|
Kichou H, Bonnier F, Dancik Y, Bakar J, Michael-Jubeli R, Caritá AC, Perse X, Soucé M, Rapetti L, Tfayli A, Chourpa I, Munnier E. Strat-M® positioning for skin permeation studies: A comparative study including EpiSkin® RHE, and human skin. Int J Pharm 2023; 647:123488. [PMID: 37805151 DOI: 10.1016/j.ijpharm.2023.123488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 09/25/2023] [Accepted: 10/04/2023] [Indexed: 10/09/2023]
Abstract
In the development and optimization of dermatological products, In Vitro Permeation Testing (IVPT) is pivotal for controlled study of skin penetration. To enhance standardization and replicate human skin properties reconstructed human skin and synthetic membranes are explored as alternatives. Strat-M® is a membrane designed to mimic the multi-layered structure of human skin for IVPT. For instance, in Strat-M®, the steady-state fluxes (JSS) of resorcinol in formulations free of permeation enhancers were found to be 41 ± 5 µg/cm2·h for the aqueous solution, 42 ± 6 µg/cm2·h for the hydrogel, and 40 ± 6 µg/cm2·h for the oil-in-water emulsion. These results were closer to excised human skin (5 ± 3, 9 ± 2, 13 ± 6 µg/cm2·h) and surpassed the performance of EpiSkin® RHE (138 ± 5, 142 ± 6, and 162 ± 11 µg/cm2·h). While mass spectrometry and Raman microscopy demonstrated the qualitative molecular similarity of EpiSkin® RHE to human skin, it was the porous and hydrophobic polymer nature of Strat-M® that more faithfully reproduced the skin's diffusion-limiting barrier. Further validation through similarity factor analysis (∼80-85%) underscored Strat-M®'s significance as a reliable substitute for human skin, offering a promising approach to enhance realism and reproducibility in dermatological product development.
Collapse
Affiliation(s)
- Hichem Kichou
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France
| | - Franck Bonnier
- LVMH Recherche, 185 Av. de Verdun, 45800 Saint-Jean-de-Braye, France
| | - Yuri Dancik
- Certara UK Ltd., Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield S1 2B1, UK
| | - Joudi Bakar
- Université Paris-Saclay, Faculté de Pharmacie, Lip(sys)(2) « Lipides, Systèmes Analytiques et Biologiques », 17 avenue des sciences, 91400 Orsay, France
| | - Rime Michael-Jubeli
- Université Paris-Saclay, Faculté de Pharmacie, Lip(sys)(2) « Lipides, Systèmes Analytiques et Biologiques », 17 avenue des sciences, 91400 Orsay, France
| | - Amanda C Caritá
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France
| | - Xavier Perse
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France
| | - Martin Soucé
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France
| | - Laetitia Rapetti
- Alphenyx, 430 avenue du Maréchal Lattre de Tassigny, 13009 Marseille, France
| | - Ali Tfayli
- Université Paris-Saclay, Faculté de Pharmacie, Lip(sys)(2) « Lipides, Systèmes Analytiques et Biologiques », 17 avenue des sciences, 91400 Orsay, France
| | - Igor Chourpa
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France
| | - Emilie Munnier
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, 31 Avenue Monge, 37200 Tours, France.
| |
Collapse
|
4
|
Mekjaruskul C, O'Reilly Beringhs A, Qin B, Wang Y, Chowdhury P, Lu X. Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products. Pharm Res 2023; 40:2239-2251. [PMID: 37679656 DOI: 10.1007/s11095-023-03586-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 08/09/2023] [Indexed: 09/09/2023]
Abstract
PURPOSE In vitro release testing (IVRT) is a widely used tool for evaluating the quality and performance of drug products. However, standardized sample adaptors or drug release apparatus setups for IVRT studies are still lacking for ophthalmic ointments. The aim of this study was to provide a better understanding of the impact of apparatus and sample adaptor setups on IVRT of ophthalmic ointments. METHODS Dexamethasone (DEX), a steroidal ingredient commonly used in ophthalmic drug products, was selected as a model drug. Ointments were prepared by mixing DEX in white petrolatum using a high shear mixer. A novel two-sided adapter was developed to increase the drug release surface area. DEX ointment was placed in one-sided or two-sided release adaptors coupled with 1.2 μm polyethersulfone membrane, and the drug release was studied in different USP apparatuses (I, II, and IV). RESULTS The sample adaptor setups had a minimal impact on cumulative drug release amount per area or release rate while USP IV apparatus with agitated flow enhanced drug release rates. The USP apparatus I with a two-sided semisolid adapter, which uses membranes on both sides, showed dramatically higher cumulative drug release and discriminative release profiles when evaluating ophthalmic formulations. CONCLUSIONS USP apparatuses and sample adaptors are critical considerations for IVRT. Two-sided semisolid adapter provides higher cumulative release, facilitating the discrimination between low drug content ophthalmic ointment formulations with good sensitivity and repeatability without affecting the drug release rate.
Collapse
Affiliation(s)
- Catheleeya Mekjaruskul
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA
- Integrative Pharmaceuticals and Innovation of Pharmaceutical Technology Research Unit, Faculty of Pharmacy, Mahasarakham University, 44150, Maha Sarakham, Thailand
| | - André O'Reilly Beringhs
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Bin Qin
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Yan Wang
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Pallabita Chowdhury
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA
| | - Xiuling Lu
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
| |
Collapse
|
5
|
Ilić T, Pantelić I, Savić S. The Implications of Regulatory Framework for Topical Semisolid Drug Products: From Critical Quality and Performance Attributes towards Establishing Bioequivalence. Pharmaceutics 2021; 13:710. [PMID: 34068036 PMCID: PMC8152494 DOI: 10.3390/pharmaceutics13050710] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 05/09/2021] [Accepted: 05/10/2021] [Indexed: 12/05/2022] Open
Abstract
Due to complex interdependent relationships affecting their microstructure, topical semisolid drug formulations face unique obstacles to the development of generics compared to other drug products. Traditionally, establishing bioequivalence is based on comparative clinical trials, which are expensive and often associated with high degrees of variability and low sensitivity in detecting formulation differences. To address this issue, leading regulatory agencies have aimed to advance guidelines relevant to topical generics, ultimately accepting different non-clinical, in vitro/in vivo surrogate methods for topical bioequivalence assessment. Unfortunately, according to both industry and academia stakeholders, these efforts are far from flawless, and often upsurge the potential for result variability and a number of other failure modes. This paper offers a comprehensive review of the literature focused on amending regulatory positions concerning the demonstration of (i) extended pharmaceutical equivalence and (ii) equivalence with respect to the efficacy of topical semisolids. The proposed corrective measures are disclosed and critically discussed, as they span from mere demands to widen the acceptance range (e.g., from ±10% to ±20%/±25% for rheology and in vitro release parameters highly prone to batch-to-batch variability) or reassess the optimal number of samples required to reach the desired statistical power, but also rely on specific data modeling or novel statistical approaches.
Collapse
Affiliation(s)
| | | | - Snežana Savić
- Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 11 221 Belgrade, Serbia; (T.I.); (I.P.)
| |
Collapse
|